It has been previously shown that STAT3 is a positive regulator of ferroptosis in KRAS-mutant pancreatic ductal adenocarcinoma cell lines.56 Strikingly, we found an increase in intracellular GSH and ROS levels in response to HOXC10 inhibition plus STAT3 inhibition in KRAS-mutant lung cancer bone metastasis cell lines (Fig. 6), implying that this drug combination, not only is an effective cancer therapy, but also can be employed as an experimental tool to clarify the underlying mechanism of ferroptosis, especially in KRAS-mutant lung cancer bone metastasis. Here, KRAS is linked to lung cancer.